StockNews.com Begins Coverage on Aeglea BioTherapeutics (NASDAQ:AGLE)

Posted by on Apr 11th, 2023

Stock analysts at StockNews.com initiated coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a report released on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Aeglea BioTherapeutics in a research report on Friday, March 3rd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1.88.

Aeglea BioTherapeutics Stock Performance

AGLE stock opened at $0.26 on Tuesday. Aeglea BioTherapeutics has a 12-month low of $0.26 and a 12-month high of $3.17. The company has a market capitalization of $17.00 million, a PE ratio of -0.26 and a beta of 1.76. The business’s fifty day moving average price is $0.39 and its 200 day moving average price is $0.56.

Hedge Funds Weigh In On Aeglea BioTherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AGLE. Nantahala Capital Management LLC raised its holdings in Aeglea BioTherapeutics by 24.3% during the 4th quarter. Nantahala Capital Management LLC now owns 4,611,302 shares of the biotechnology company’s stock worth $2,075,000 after buying an additional 900,524 shares during the period. Millennium Management LLC lifted its position in shares of Aeglea BioTherapeutics by 284.4% in the 4th quarter. Millennium Management LLC now owns 3,131,479 shares of the biotechnology company’s stock valued at $1,409,000 after acquiring an additional 2,316,807 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in Aeglea BioTherapeutics by 14.8% in the 1st quarter. Rock Springs Capital Management LP now owns 1,811,425 shares of the biotechnology company’s stock worth $4,166,000 after purchasing an additional 234,129 shares during the period. Goldman Sachs Group Inc. grew its position in Aeglea BioTherapeutics by 5.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company’s stock worth $600,000 after purchasing an additional 62,504 shares in the last quarter. Finally, Pura Vida Investments LLC acquired a new stake in Aeglea BioTherapeutics during the 4th quarter valued at $472,000. 78.01% of the stock is currently owned by institutional investors and hedge funds.

About Aeglea BioTherapeutics

(Get Rating)

Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.

Featured Stories

Analyst Recommendations for Aeglea BioTherapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.